RenaissThera, a biotechnology company based in Bengaluru, India, has achieved a significant milestone in its obesity drug discovery program. The company is focusing on targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), which is an incretin receptor known for its effectiveness in treating obesity and related conditions. RenaissThera is working on developing novel oral small molecules, including both agonists and antagonists, to provide a more affordable and convenient option for underserved populations in the global obesity market.

These oral small molecules are more cost-effective to produce and distribute compared to peptide-based drugs. They were designed and screened using proprietary artificial intelligence (AI) and machine learning (ML) platforms, showing promising in-vitro and in-vivo activity in impacting GIPR in mice. RenaissThera is now moving forward with these findings to the Lead optimization program in preparation for pre-IND studies.

The company is also securing patents for these oral small molecule GIPR modulators and expanding its innovation portfolio to target other receptors involved in obesity and diabetes. By leveraging AI-powered tools like GenAI and machine learning, RenaissThera aims to accelerate the design and optimization of novel small molecules for therapeutic purposes.

Dr. Ramkesh Meena, the CEO of RenaissThera, expressed gratitude to investors and collaborators for their support in achieving this milestone. The team is now focused on advancing candidates towards IND-readiness and is actively engaging with potential pharmaceutical partners and investors interested in their obesity program.

RenaissThera's collaboration with VedTechBio Research Private Limited, which provided access to the Agentic AI platform RxAgentAI and discovery expertise, played a crucial role in their progress. This milestone further validates the platform and capabilities of both companies in key therapeutic areas such as obesity, Type 2 diabetes, oncology, and inflammation.

RenaissThera is a biotech company based in Bengaluru, India, dedicated to developing affordable, AI-powered small-molecule therapies for diseases like obesity and diabetes. Their focus is on innovating for underserved populations and expanding global access to novel treatments. By leveraging India's CRO ecosystem for early-stage research and development, RenaissThera aims to deliver innovative solutions with global relevance.

For more information, visit www.renaissthera.com

Media Contact:
Lakshmi Ramakrishna - [email protected]

Investor & Partnership Contact:
Ramkesh Meena - [email protected]